Cajanding Ruff
Staff Nurse, Liver Intensive Therapy Unit, Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London.
Br J Nurs. 2018 Sep 6;27(16):920-927. doi: 10.12968/bjon.2018.27.16.920.
Solid organ transplantation has revolutionised medical care by providing a definitive cure for a wide spectrum of end-stage medical conditions. This treatment, however, does not come without complications and poses the risks of rejection, life-threatening infection, malignancies and recurrent organ failure, with significant impacts on patient outcomes. One of the major challenges involved in optimising post-transplant outcomes is managing the immune system's response to the transplanted graft and preventing organ rejection. This is mainly accomplished through the use of immunosuppressant agents, which have become a mainstay of treatment for a majority of post-transplant patients. This article, the first of two parts, discusses the concept of immunosuppression and its importance in the care of patients who have received an organ transplant. It focuses on the pathophysiologic mechanisms involved in transplant rejection and discusses the pharmacologic aspects of immunosuppression and its implications for patient care.
实体器官移植通过为广泛的终末期疾病提供确切的治疗方法,彻底改变了医疗护理。然而,这种治疗并非没有并发症,存在排斥反应、危及生命的感染、恶性肿瘤和器官功能复发衰竭的风险,对患者的治疗结果有重大影响。优化移植后治疗结果所涉及的主要挑战之一是管理免疫系统对移植器官的反应并预防器官排斥。这主要通过使用免疫抑制剂来实现,免疫抑制剂已成为大多数移植后患者治疗的主要手段。本文是两部分系列文章的第一篇,讨论免疫抑制的概念及其在器官移植患者护理中的重要性。它重点关注移植排斥反应所涉及的病理生理机制,并讨论免疫抑制的药理学方面及其对患者护理的影响。